Shopping Cart
Remove All
Your shopping cart is currently empty
Talquetamab (Synonyms: JNJ-7564, JNJ-64407564)
Catalog No. T76882 Copy Product Info
🥰Excellent
Talquetamab (JNJ-64407564) is a GPRC5D bispecific antibody for multiple myeloma (MM) that induces T-cell-mediated killing of GPRC5-expressing MM cells through T-cell recruitment and activation, demonstrating antitumor activity.
Talquetamab
Copy Product Info🥰Excellent
Catalog No. T76882
Synonyms JNJ-7564, JNJ-64407564
Talquetamab (JNJ-64407564) is a GPRC5D bispecific antibody for multiple myeloma (MM) that induces T-cell-mediated killing of GPRC5-expressing MM cells through T-cell recruitment and activation, demonstrating antitumor activity.
Cas No. 2226212-40-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | In Stock | In Stock | |
| 2 mg | $437 | - | In Stock | |
| 5 mg | $723 | In Stock | In Stock | |
| 10 mg | $1,160 | - | In Stock | |
| 25 mg | $1,720 | - | In Stock | |
| 50 mg | $2,320 | - | In Stock | |
| 100 mg | $3,130 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.6% (SDS-PAGE); 99.7% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Talquetamab (JNJ-64407564) is a GPRC5D bispecific antibody for multiple myeloma (MM) that induces T-cell-mediated killing of GPRC5-expressing MM cells through T-cell recruitment and activation, demonstrating antitumor activity. |
| In vitro | Talquetamab, at concentrations ranging from 0.00128 to 4.0 μg/mL for 48 hours, effectively induces lysis of multiple myeloma cells. This induction is accompanied by a significant dose-dependent increase in the proportion of activated CD4+ and CD8+ T cells, as well as elevated levels of granule enzyme B and inflammatory cytokines such as IL-6, IL-8, and TNF-α [2]. |
| In vivo | Talquetamab (JNJ-64407564), administered subcutaneously or intravenously at doses ranging from 0.1 to 50 µg, exhibits significant anti-tumor activity in H929 and MM mouse models [1]. |
| Synonyms | JNJ-7564, JNJ-64407564 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | GPRC5D & CD3 |
| Molecular Weight | 144.59 kDa |
| Cas No. | 2226212-40-2 |
| Isotype | IgG4 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Talquetamab | purchase Talquetamab | Talquetamab cost | order Talquetamab | Talquetamab chemical structure | Talquetamab in vivo | Talquetamab in vitro | Talquetamab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.